CANbridge Pharmaceuticals Inc.
Research CANbridge Pharmaceuticals Inc. (1228.HK) on Bullrun: market cap HKD 963.46M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1228.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 963.46M
- Financial periodFY2025
- RevenueCNY 49.98M
- Revenue growth-41.3%
- Net incomeCNY 14.82M
- Free cash flow-CNY 38.22M
- Gross margin74.7%
Valuation Snapshot
latest market cap is HKD 963.46M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 49.98M | CNY 14.82M | -CNY 38.22M | 74.7% | 0.03 | CNY 66.63M | CNY 16.08M | -CNY 341.76M |
| FY2024 | CNY 85.10M | -CNY 442.62M | -CNY 122.50M | 63.8% | -1.04 | CNY 10.03M | CNY 135.78M | -CNY 474.49M |
| FY2023 | CNY 102.87M | -CNY 378.84M | -CNY 319.09M | 62.4% | -0.89 | CNY 124.90M | CNY 141.93M | -CNY 39.79M |
| FY2022 | CNY 78.97M | -CNY 483.48M | -CNY 315.77M | 61.9% | -1.14 | CNY 451.16M | CNY 155.28M | CNY 308.56M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 963.46M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CANbridge Pharmaceuticals Inc.'s market cap?
CANbridge Pharmaceuticals Inc.'s market capitalization is HKD 963.46M.
What does CANbridge Pharmaceuticals Inc. do?
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis.